Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Change in Receivables for 3 consecutive years, with $22.3 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 25.89% to $22.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.3 million through Dec 2025, up 5.84% year-over-year, with the annual reading at $39.3 million for FY2025, 5.84% up from the prior year.
  • Change in Receivables for Q4 2025 was $22.3 million at Phathom Pharmaceuticals, up from $4.5 million in the prior quarter.
  • The five-year high for Change in Receivables was $22.3 million in Q4 2025, with the low at -$2.4 million in Q1 2025.
  • Average Change in Receivables over 3 years is $8.7 million, with a median of $7.0 million recorded in 2024.
  • The sharpest move saw Change in Receivables soared 984.0% in 2024, then tumbled 208.47% in 2025.
  • Over 3 years, Change in Receivables stood at $1.6 million in 2023, then skyrocketed by 984.0% to $17.7 million in 2024, then increased by 25.89% to $22.3 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $22.3 million, $4.5 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.